Equal Access to Medical Care for All with AI
~ FRONTEO believes in the growth of people and technology ~
AI x natural language
FRONTEO's Philosophy about Life Science AI
Our Life Science AI business is based on the idea of challenging medical problems and materializing a society where anyone can access reliable medical care.
We work with experts in various fields to promote “Patient First, Evidence-based” R & D and create various solutions.
Natural language processing AI
Specialized in the life science field
Concept Encoder is an artificial intelligence (AI) originally developed by FRONTEO. It was developed in 2018 with the purpose of effectively analyzing and utilizing medical data that contains a large amount of freely described text data based on evidence.
We have introduced and implemented statistical methods for natural language processing, such as significant difference tests, which are essential for "evidence-based medicine (EBM)," which is common among healthcare workers. FRONTEO is researching and developing various solutions using Concept Encoder. Patent registration number: Patent No. 6346367
No dictionary required
Any languages available
Analyse with biochemical
Process words and sentences
at once, and
Quickly implemented and requires low machine power
AI for Drug discovery support
We support efficient drug discovery research with the “Drug Discovery Research Support AI System”, which visualizes information in articles, and speeds up the search for target molecules and biomarker candidates.
Our proprietary AI "Concept Encoder" enables highly accurate analysis in a short period of time, and reduces the time and cost required for drug development.
AI Diagnosis and Digital Health
It is expected that the technology of natural language processing by "Concept Encoder" will play an important role in assisting to diagnose diseases which are diagnosed based on interviews.
We are researching and developing a dementia diagnosis support system and Fall prediction system "Coroban®" with AI.
Business Management Support
We support to collect drug safety information and investigate for side effects using AI.
We also provide AI support for MR sales and SNS analysis for diseases.
Tokyo Medical and Dental University
Medical Economics Field
Professor for Graduate
He graduated from Hitotsubashi University's Faculty of Commerce and management in 1983, and earned an MBA from the University of Chicago School of Business in 1987. After working at private hospitals and companies, worked for the Ministry of Health, Labour and Welfare at the National Institute of Health and Medical Care (currently the National Institute of Health Sciences) from 1989 to 1998. Retired from the Ministry of Health and Welfare in 1998. In April of the same year, he concurrently hold a professor at the Faculty of Economics of Nihon Fukushi University, a senior researcher at the JMARI (Japan Medical Associate Research Institution), a Faculty Fellow at the Ministry of Economy, Trade and Industry, and a visiting researcher at Stanford University. Appointed to current position since April 2000. He also hold a visiting professor at the Japan China Friendship Clinic, an emeritus professor at Shenyang Medical College, a visiting professor at Ningxia Medical University, and a special member of the China Hygiene Industry Magazine Special Committee. Recent publications include "How Does the Landscape Change?-Pharmacy in 2040 (Yakuji Nippo, Limited, 2016)", "The Key to the Success of Comprehensive Community Care System (Japan Municipal Research Center, 2015)", "Visualization, Introduction to Medical Economics (Ishiyaku Publishers,Inc., 2014)", "Points of the Sixth Medical Law Revision and Response Strategy 60 (Japan Medical Planning, 2014)", "Still save univarsal health insurance (JIYUKOBO Inc., 2011), “Is Medical Regeneration Possible? (Chikumashobo Ltd., 2008)”, “Dignity of Hospital (Japan Medical Planning, 2008)”. As a social activity, He also holds councilor and director of Japan Society for Healthcare Administration, councilor of Japanese Society for Clinical Pathway, chairman of Ripplet Foundation, director of Nihon Kaigo Fukushi keiei jinzai Kyouiku kyoukai, standing director of Research Association of Health Hospital Services, etc. Received a welfare policy research grant Award (October 1997), 4th Mix Award (November 1998), AJHC (Association of Japanese Healthcare Corporations) 50th Anniversary Sweepstakes Award (April 2001), Japan Medical Association's Medical Convention for54th founding commemoration "Japan Medical Association Achievement Award" (November 2001, 10-year member of the Japan Medical Association Committee).
Ph.D. Hiroyoshi Toyoshiba
Life Science AI Division Life Science AI Chief Technology Officer
Graduated Waseda University Graduate School of Science and Engineering majored Mathematics. He has been in charge of statistical analysis of medical data at the Medical Information Department of Kyushu University Hospital since 1999 during his Ph.D. (Mathematics, Ph.D. in 2000) course. Since 2000, he has been participating in research on carcinogenic processes by data analysis at the National Institute of Environmental Health Sciences (NIEHS) in the United States. Since 2004, has been engaged in the design of statistical analysis and epidemiological study of toxicity data and research of data analysis at the National Institute for Environmental Studies. He joined Takeda Pharmaceutical Company Limited in 2006 and has been a researcher of bioinformatics, a head of the Global Data Science Research Institute / Japan Site Bioinformatics, and a science fellow. He is also involved in gene expression data analysis and target search in clinical trial data, and biomarker search in immunity and cancer.
Head of Business Strategy
Pharmacist / MBA
After joining Astellas Pharma (former Fujisawa Pharmaceutical), started his career as sales (MR), he experienced numerous product marketing, product evaluation, and business area strategy planning, mainly for transplant immunity, rare diseases, respiratory diseases, etc. After that, he was appointed as the head of sales and marketing at the pharmaceutical venture SymBio Pharmaceuticals. Focusing on building an in-house sales system, he has been involved in launching organizations about the blood cancer, introducing products, marketing alliances, and building digital strategies. At FRONTEO, he supervises business strategy and marketing.
Ph.D. Takanori Ueda
R & D Department Research Team
After completing a doctoral course in biofunctional science at the Graduate School of Bioresources and Environmental Sciences, Kyushu University in 2004, he joined National Institute of Advanced Industrial Science and Technology. In the development of technology to introduce genes into cells, he analyze large-scale phenotype data and time-series data of cells and develop modeling techniques. After that, he joined a bio-venture company spun out by the research team, and was in charge of analyzing phenotypic data and developing algorithms of various cells, and managing systems. In 2015, he was appointed Research Manager, and was involved in marketing, new joint research and business alliances, and the development of new products for cell experiments. As a senior researcher at FRONTEO, he is responsible for the research of the Fall prediction system “Coroban®”.
Ph.D. Ryota Mizushima
R & D Department Research Team
After studying biology and physics at the Faculty of Liberal Arts, the University of Tokyo, he entered the Graduate School of Life Sciences, Osaka University. He earned a Ph.D. from the Institute for Protein Research, Osaka University, for studying the structural analysis of DNA mismatch repair proteins related to hereditary colorectal cancer by nuclear magnetic resonance (NMR). After that, he joined RIKEN Biosystems Research Center (currently, Biofunctional Science Research Center) researched on genetically-encoded hyperpolarized 129Xe MRI contrast agents using biotechnology-based genes of bacterial protein nanoparticles. After that, he became an assistant professor at Tokyo Medical University's Nanoparticle Advanced Medicine Application Course. After it engaged in the study of protein decomposition inducing agent, in charge of the joint research with Keio University School of Medicine of dementia diagnosis support system as a researcher in FRONTEO, engaged in analysis of the conversation text data of neuropsychiatric disease patient using Concept Encoder and a deep learning.
Announcement of video commentary on novel coronavirus infectious disease research
Research on novel coronavirus infectious disease (COVID-19) using AI, FRONTEO found about 450 candidate compounds.
FRONTEO succeeded analysing effective mechanism to select of therapeutic drug candidates for novel coronavirus infectious disease (COVID-19), using AI.